Chengdu Easton Biopharmaceuticals (SHA:688513), through unit Shanghai Chaoyang Pharmaceutical, enrolled the first subject for the clinical trial of HP-002 tablets, according to a Shanghai bourse filing on Thursday.
The trial, which is in phase I/II, invited patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The drug's safety and tolerability will be tested in the patients.
The pharmaceutical company's shares jumped 2% during the afternoon trade.